BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available
December 16 2020 - 9:30AM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce that its subsidiary, BioSyent Pharma Inc., has
commenced the first shipments of Combogesic® to Canadian
wholesalers. Combogesic® is the first fixed-dose combination of
acetaminophen and ibuprofen in a single tablet in Canada and is
indicated for the short-term management of mild to moderate acute
pain and the reduction of fever in adults.
Combining two trusted, familiar, and effective
active ingredients, acetaminophen and ibuprofen, in a new patented
formulation, Combogesic® brings together two different modes of
action into one effective pain reliever. Though the two active
ingredients have been available in Canada for decades, Combogesic®
represents the first Health Canada approved combination of these
proven pain relievers in a single tablet.
“A novel combination of two popular
non-prescription analgesics – ibuprofen and acetaminophen –
Combogesic® provides clinicians with an additional therapeutic
option for achieving multimodal analgesia for mild to moderate pain
management in adults without compromising the well-established
safety profile of either active constituent,” said Dr. Nardine
Nakhla, a community pharmacist and clinical lecturer at the
University of Waterloo School of Pharmacy.
BioSyent Pharma Inc. in-licensed Combogesic® for
Canada from AFT Pharmaceuticals Ltd. who market the product, either
directly or through partners, to 44 other countries under various
brand names including Maxigesic®. In other markets it comes in
different dosage forms and strengths. The efficacy of Combogesic®
is based on its clinically proven unique ratio – one tablet
contains 325 mg of acetaminophen and 97.5 mg of ibuprofen, a 3.3:1
ratio.
Combogesic® has a well-established safety and
tolerability profile and is opioid-free. The safety of Combogesic®
is comparable to similar doses of either acetaminophen or ibuprofen
alone. Examples of acute pain include headaches, menstrual cramps,
sprains, and strains. Acute pain can also occur from tissue
injuries and after surgical operations.
“We are pleased to make Combogesic® available to
Canadians as a new option for the management of acute pain and
reduction of fever,” said René Goehrum, President and CEO of
BioSyent. “Canadians consume over 2.7 billion doses of analgesics
annually to treat acute pain or fever and our research tells us
that a portion of this market is not satisfied. We are excited to
achieve this milestone of bringing Combogesic® to the market and to
have it contribute to the long-term growth and diversification of
our Canadian pharmaceutical business.”
Combogesic® is available without a prescription
by simply asking at the pharmacy counter or by ordering
on-line.
You can find more information about Combogesic®
at www.Combogesic.ca
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty/hospital and international business units.
As of the time of this press release, the
Company has 12,805,200 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a4a060-1c11-4af4-8e1d-8f245ff50f9d
Biosyent (TSXV:RX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Oct 2023 to Oct 2024